Back

Association between PCSK9 inhibitor with cause-specific morality amongst cancer survivors

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology: treatments and outcomes Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Tong Liu

2nd Hospital of Tianjin Medical University, Tianjin (China)

9 More presentations in this session

Presentation thumbnail
The impact of peptide receptor radionucleotide therapy with Lutetium-177 DOTATATE on cardiac metastases in neuroendocrine tumors
Associate Professor C. Ayoub (Phoenix, US)
Abstract Slides Video
Presentation thumbnail
The predictive value of coronary artery calcium deposit for cardiovascular events in patients treated with immune checkpoint inhibitor therapy
Doctor M. Slieman (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Long term risk of heart failure in adult cancer survivors: a systematic review and meta-analysis
Doctor J. Wong (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Assessment of right ventricular dysfunction in breast cancer patients undergoing anthracycline and trastuzumab treatment
Doctor M. Santa Ana Bayona (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Incidence of acute cardiovascular hospitalizations and association with hemodynamic biomarkers in cancer patients treated with Immune Checkpoint Inhibitor therapy
Doctor C. Mann (Vienna, AT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology: treatments and outcomes

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Proprotein convertase subtilisin/kexin type 9 levels and the risk of cardiovascular events in statin-treated patients with cardiovascular disease
thumbnail
Congress Presentation
Efficacy of PCSK9 inhibitors combined with statins versus statin monotherapy for secondary cardiovascular prevention: a systematic review and meta-analysis
thumbnail
Congress Presentation
Lower rate of ischemic events with PCSK9 inhibition in patients with atherosclerotic cardiovascular disease but without prior ischemic events

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources